Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Income towards Parent Company (2020 - 2025)

Historic Income towards Parent Company for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to -$14.6 million.

  • Barinthus Biotherapeutics' Income towards Parent Company fell 7924.71% to -$14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.9 million, marking a year-over-year decrease of 3120.83%. This contributed to the annual value of -$61.2 million for FY2024, which is 1669.78% up from last year.
  • Barinthus Biotherapeutics' Income towards Parent Company amounted to -$14.6 million in Q3 2025, which was down 7924.71% from -$21.1 million recorded in Q2 2025.
  • Barinthus Biotherapeutics' Income towards Parent Company's 5-year high stood at $15.7 million during Q2 2022, with a 5-year trough of -$23.8 million in Q2 2023.
  • For the 5-year period, Barinthus Biotherapeutics' Income towards Parent Company averaged around -$12.2 million, with its median value being -$16.8 million (2021).
  • In the last 5 years, Barinthus Biotherapeutics' Income towards Parent Company soared by 24868.87% in 2022 and then crashed by 80796.43% in 2023.
  • Barinthus Biotherapeutics' Income towards Parent Company (Quarter) stood at -$16.8 million in 2021, then decreased by 25.69% to -$21.2 million in 2022, then grew by 18.3% to -$17.3 million in 2023, then fell by 19.09% to -$20.6 million in 2024, then rose by 29.24% to -$14.6 million in 2025.
  • Its last three reported values are -$14.6 million in Q3 2025, -$21.1 million for Q2 2025, and -$19.7 million during Q1 2025.